Pregabalin is an antiepileptic agent primarily indicated for the clinical treatment of postherpetic neuralgia.

Effective April 20, 2026, the National Medical Products Administration (NMPA), the Ministry of Public Security, and the Office of the National Narcotics Control Commission have jointly issued a circular to further strengthen the full-chain regulation of addictive substances, including oral single-agent pregabalin formulations, aiming to resolutely curb the spread of pharmaceutical abuse.

AccuSift provides high-performance competitive antibody pairs for pregabalin detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 20 ng/mL